

1 **Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity**
2 **and increase antioxidant activity**

3 Jose Carlos de Lima-Junior¹, Vitor W.M. Virginio¹, Filipe A. Moura^{1,2}, Adriana Bertolami³,
4 Marcelo Bertolami³, Otavio R Coelho-Filho⁴, Ilaria Zanotti⁶, Wilson Nadruz⁴, Eliana Cotta
5 de Faria⁵, Luiz Sergio F. de Carvalho^{1,4}, Andrei C Sposito^{1,4}

6 1. Laboratory of Atherosclerosis and Vascular Biology, Faculty of Medical Sciences, State
7 University of Campinas, São Paulo, Brazil

8 2. Department of Cardiology, Brigham and Women's Hospital, Boston, New England,
9 United States

10 3. Department of Dyslipidemia, Dante Pazzanese Cardiological Institute, São Paulo, Brazil

11 4. Department of Internal Medicine, Cardiology Division, Faculty of Medical Sciences,
12 State University of Campinas, São Paulo, Brazil

13 5. Lipids Laboratory, Department of Clinical Pathology, Faculty of Medical Sciences,
14 State University of Campinas, Sao Paulo, Brazil

15 6. Department of Food and Drug, University of Parma, Parma, Italy

16 To whom correspondence should be addressed. E-mail: andreisposito@gmail.com

17 **Corresponding author:**

18 Andrei C Sposito

19 Cardiology Division, State University of Campinas

20 13084-971, Campinas, São Paulo, Brazil

21 andreisposito@gmail.com

22 **Running title:** Excess weight and HDL functions

23 The authors declare no conflict of interest.

24 **Keywords** - atherosclerosis; cholesterol efflux; HDL metabolism; HDL; obesity

25

26

27

28 **Abbreviations:** ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; AST,
29 aspartate aminotransferase; CE, cholesteryl ester; CEC, Cholesterol efflux capacity; CETP,
30 cholesteryl ester transfer protein; cIMT, carotid intima-media thickness; FC, free cholesterol;
31 HL, hepatic lipase; HOMA2 % β , Homeostasis model assessment 2 of beta-cell function;
32 HOMA2-IR, Homeostasis model assessment 2 of insulin resistance; HOMA2 %S, Homeostasis
33 model assessment 2 of insulin sensitivity; HUVEC, human umbilical vein endothelial cells;
34 LCAT, Lecithin-cholesterol acyltransferase activity; PL, phospholipids; LPL, Lipoprotein
35 lipase; PON, paraoxonase; TC, total cholesterol; PLTP, phospholipids transfer protein; VCAM-
36 1, vascular cell adhesion molecule-1.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abstract:**

52 **Objective:** Obesity-related decline in high-density lipoprotein (HDL) functions such as
53 cholesterol efflux capacity (CEC) has supported the notion that this lipoprotein dysfunction may
54 contribute for atherogenesis among obese patients. Besides, potentially other HDL protective
55 actions may be affected with weight gain and these changes may occur even before the obesity
56 range.

57 **Methods:** Lipid profile, body mass index (BMI), biochemical measurements, and
58 carotid intima-media thickness (cIMT) were obtained in this cross-sectional study with 899
59 asymptomatic individuals. HDL functions were measured in a subgroup (n=101).

60 **Results:** Individuals with increased HDL-C had an attenuated increase in cIMT with
61 elevation of BMI. CEC, HDL-C, HDL size and HDL-antioxidant activity were negatively
62 associated with cIMT. BMI was inversely associated with HDL-mediated inhibition of platelet
63 aggregation and CEC, but surprisingly it was directly associated with the antioxidant activity.
64 Thus, even in non-obese, non-diabetic individuals, increased BMI is associated with a wide
65 change in protective functions of HDL, reducing CEC and increasing antioxidant activity. In
66 these subjects, decreased HDL concentration, size or function are related to increased
67 atherosclerotic burden.

68 **Conclusion:** Our findings demonstrate that in non-obese, non-diabetic individuals, the
69 increasing values of BMI are associated with impaired protective functions of HDL and
70 concomitant increase in atherosclerotic burden.

71

72

73

74

75

76

77

78 **1. Introduction**

79 Presently, one in three individuals with excess weight will die from cardiovascular
80 disease (CVD)[1, 2]. In fact, both obesity (BMI >30 kg/m²) and overweight (BMI of 25 to <30
81 kg/m²) individuals are at increased risk of cardiovascular death as compared with those with
82 BMI within the normal range (18.5 to <25 kg/m²)[3]. The proposed milieu for this interaction
83 involves a spectrum of mechanisms in which phenotypic or functional changes in high-density
84 lipoprotein (HDL) are involved [4].

85 The identification of HDL involvement in adiposopathy is not a recent issue. Since the
86 metabolic syndrome was conceived, all clinical criteria for its diagnosis included low levels of
87 plasma HDL-cholesterol (HDL-C) as a marker of metabolically, unhealthy obesity. In the
88 mechanistic point of view, the combination of increased substrate, such as triglyceride-rich
89 lipoproteins, and increased activity of HDL remodeling proteins, such as cholesteryl ester
90 transfer protein (CETP), and hepatic lipase (HL), coexists in overweight individuals as a result
91 of insulin resistance, promoting a reduction in HDL concentration, size and its content of
92 apolipoproteins AI (ApoA-I). In addition, a decrease in the overall cholesterol efflux capacity
93 (CEC) has been reported in obese subjects [5], despite the increased ABCA1-mediated
94 cholesterol efflux[6].

95 Besides CEC, HDL also mediates several other anti-atherosclerotic mechanisms, such
96 as antioxidant, anti-inflammatory activities and inhibition of platelet aggregation, whose extent
97 is sensitive to phenotypic changes of the particles, such as those described above. If this is so,
98 more than the reduced capacity as free cholesterol acceptor, an overall dysfunction in the HDL
99 system may follow weight gain [7]. Furthermore, as the magnitude of these phenotypic changes
100 in HDL occurs in parallel with the increase in BMI, it is possible that a cluster of particle
101 dysfunctions occurs earlier with the weight gain, possibly even before the criterion for
102 overweight. Hence, a metabolic legacy related to HDL may contribute to the future CVD risk.
103 In order to shed some light on these gaps, we designed this study to evaluate the impact of BMI

104 on the interaction between HDL concentration and functions with atherosclerotic burden in pre-
105 obese individuals.

106 **2. Materials and methods**

107 **2.1. Cross-sectional study description**

108 We evaluated a sample of 899 asymptomatic individuals who were seen in two primary
109 care centers between 2008 and 2013: the outpatient clinic at Dante Pazzanese Institute of
110 Cardiology, São Paulo (SP), Brazil, and governmental primary care centers of the city of
111 Campinas, SP, Brazil. Inclusion criteria were: (1) no manifested atherosclerotic CVD; (2) no
112 diagnosis of type 2 diabetes based on antidiabetic treatment, fast blood glycemia ≥ 126 mg/dL,
113 glycated hemoglobin $\geq 6.5\%$ or glycemia ≥ 200 mg/dL on 120-minutes oral tolerance test and (3)
114 age between 20 and 75 years old. We excluded individuals with (1) uncontrolled hyper (thyroid
115 stimulating hormone (TSH) $< 0.41 \mu\text{UI/mL}$ or free thyroxin $> 1.8 \text{ ng/dL}$) or hypothyroidism
116 (TSH $> 4.50 \mu\text{UI/mL}$ or free thyroxin $< 0.9 \text{ ng/dL}$); (2) antidiabetic medications; (3) liver disease,
117 as indicated by ALT or AST over two times the upper limit; (4) urea $> 40 \text{ mg/dL}$; (5) glomerular
118 filtration rate $\leq 60 \text{ mL/min/1.73m}^2$; (6) heart failure NYHA stage $\geq \text{III}$; (7) HIV positive or (8)
119 withdrawal of informed consent. Patients underwent clinical examination, as well as
120 biochemical analysis. Subclinical atherosclerosis was measured in all patients up to a month
121 after being included. The study was approved by the local institutional ethical committee of the
122 Instituto Dante Pazzanese de Cardiologia (registration number 3852/2009). It is also registered
123 at ClinicalTrials.Gov by the identification NCT02487615. All patients provided written and
124 informed consent forms before taking part in the study. The study protocol conforms to the
125 ethical guidelines of the 1975 Declaration of Helsinki.

126 A sub-analysis testing functions and characteristics of HDL was performed in
127 consecutive sample of 101 individuals from the enrolled participants in the governmental
128 primary care centers of the city of Campinas. The study was approved by the local institutional
129 ethical committee of the Hospital das Clínicas of the State University of Campinas (registration
130 number 1260/2010). It is registered at ClinicalTrials.Gov by the identification NCT02106013.

131 All patients provided written and informed consent forms before taking part in the study. The
132 study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

133 **2.2. Biochemical analysis**

134 Blood samples were drawn after a 12-hour fasting period. The following biochemical
135 measurements were performed: triglycerides, total cholesterol, HDL-C, creatinine, c-reactive
136 protein (CRP), insulin, glucose, and insulin. LDL-C was calculated using Friedewald's
137 equation. Glomerular filtration rate was calculated by the CKD-EPI equation. HOMA2 % S,
138 HOMA2-IR and HOMA2 β were calculated using computer models [8].

139 **2.3. Carotid artery ultrasound**

140 Carotid Doppler ultrasound was performed using high-resolution Vivid 7 ultrasound
141 (GE, USA) and high-frequency linear transducer (9 MHz) with automatic border recognizer
142 detection as described previously in Bertolami et al [9]. Briefly, the cIMT was obtained by
143 means of image processing of B-mode ultrasonograms of the right and left automatic
144 measurement. High-resolution B-mode ultra-sonographic imaging was performed initially
145 evaluating the common carotid artery with antero-oblique insonation above the clavicle and
146 alongside the internal carotid artery, as standardized procedure[10]. Measurement of cIMT was
147 obtained 20 mm proximally from the carotid bifurcation as the distance between the lumen-
148 intima interface and the media-adventitia interface[11].

149 **2.4. Lipoprotein isolation**

150 LDL was isolated from a pool of normolipidemic sera from 20 volunteers, through
151 sequential ultracentrifugation using a Beckman L8-M ultracentrifuge (Beckman Coulter Inc.,
152 Palo Alto, USA), with a 75Ti fixed angle rotor (Havel, 1955 #11). HDL was isolated from each
153 study participant through density gradient ultracentrifugation[12] with the use of a SW41Ti
154 rotor. Isolated lipoproteins were extensively dialyzed against EDTA-free PBS for 24h, at 4°C, in
155 a dark room. All assays were performed in freshly isolated lipoproteins that were kept at 4°C for
156 a maximum period of 15 days.

157 **2.5. HDL chemical composition and molar concentration measurements**

158 HDL chemical composition was measured using commercially available enzymatic kits,
159 in the microplate reader Power Wave XS (BioTek®, Winooski, USA). Total proteins (Pierce™
160 BCA Protein Assay Kit, Thermo Scientific, Rockford, USA), TC (CHOD-PAP, total
161 cholesterol, Roche Diagnostics® reagents, Mannheim, Germany), FC (Free Cholesterol E,
162 Wako Chemicals, Richmond, USA), PL (Phospholipids C, Wako Chemicals, Richmond, USA),
163 TG (TG, GPO-PAP, Roche Diagnostics® reagents, Mannheim, Germany) and ApoA-I (TINA
164 QUANT APOA1 V2, Roche Diagnostics® reagents, Mannheim, Germany) were measured,
165 while CE was calculated according to the following formula: $(TC-FC) \times 1.67$ [12]. The relative
166 content of ApoA-I (HDL-ApoA-I) or lipids in HDL was calculated based on their proportion to
167 the total mass of HDL, calculated as the sum of FC, PL, TG, CE, and total proteins. HDL molar
168 concentration was estimated based on particle total mass and molecular weight[12].

169 **2.6. HDL physical-chemical characterization**

170 HDL particle size was determined using dynamic light scattering, in a Nanotracs Particle
171 Size Analyser 250 (Microtracs Inc., Montgomeryville, USA)[13]. Zeta potential was determined
172 in HDL diluted 1:10 in KCl 10mM, using laser Doppler micro-electrophoresis, in the Zetasizer
173 Nano ZS (Malvern Instruments, Malvern, UK).

174 **2.7. Determination of proteins involved in HDL metabolism**

175 CETP and PLTP activities were measured using exogenous radiometric assays, as
176 previously described[14, 15]. LPL and HL activities were measured in fasted post-heparin
177 plasma samples, collected 15min after the intravenous administration of heparin (100U/kg body
178 weight), in an assay based on fatty acid release from a radiolabeled triolein emulsion[16]. LCAT
179 activity was determined using recombinant HDL, according to standardized method [17]. PON
180 activity was measured using paraoxon (diethyl-p-nitrophenylphosphate, Sigma, St. Louis, MO,
181 USA) as substrate [18].

182 **2.8. HDL antioxidant activity**

183 HDL antioxidant activity was measured in a kinetic fluorimetric assay adapted from
184 Navab et al[19]. Oxidation was monitored as changes in the fluorescence intensity of 2',7'-
185 dichlorofluoresceine (DCFH). For the antioxidant activity assays, LDL (final concentration,

186 20mgTC/dL) and CuSO₄ (final concentration, 0.5μM) were added to DCFH-containing tubes
187 (final concentration, 2mg/mL), followed by the addition or not of HDL (final concentration,
188 15mg total mass/dL). The volume was adjusted to 100μL with Chelex treated-PBS and the
189 reaction mixture transferred onto a black 96-well microplate. The plate was covered with an
190 optical adhesive cover to avoid evaporation and incubated at 37°C. Fluorescence intensity was
191 measured over 24h with 15-minute intervals in a fluorescence microplate reader (Spectra Max
192 M5; Molecular Devices, Sunnyvale, USA) at an excitation wavelength of 485nm, emission
193 wavelength of 540 nm, and cut-off of 530nm. Results of antioxidant activity are presented as the
194 percentage of inhibition of LDL oxidation in the presence of each subject's HDL when
195 compared to control wells (LDL alone).

196 **2.9. HDL anti-inflammatory activity**

197 HDL's anti-inflammatory activity was measured in HUVEC in an assay adapted from
198 Besler et al[20]. Cells were cultured in RPMI 1640 medium containing 10% fetal calf serum,
199 penicillin, and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching
200 confluence, they were plated in 24-well culture plate (3 x 10⁵ cells/well, and incubated with
201 TNF-α (1ng/mL), with or without HDL (50μg ApoA-I/mL) for three hours. The culture media
202 were collected and stored at -80°C. Due to the low VCAM-1 concentrations, samples were
203 concentrated using the Amicon® Ultra Centrifugal Filters, 50K (Millipore, Massachusetts,
204 USA) and then VCAM-1 concentrations were measured using the Human VCAM-1 ELISA Kit
205 (Cat number ECM340, Millipore, Massachusetts, USA). Results are expressed as the percentage
206 of decrease in VCAM-1 concentrations in the wells incubated with HDL when compared to the
207 control wells without HDL.

208 **2.10. Cholesterol efflux capacity (CEC) assay**

209 Global cellular CEC was performed using J774 macrophages enriched with acetylated
210 LDL and ¹⁴C-cholesterol and HDL as the cholesterol acceptor[21]. In summary, J774
211 macrophages were cultured in RPMI 1640 medium containing 10% fetal calf serum, penicillin,
212 and streptomycin and maintained in a 5% CO₂ incubator at 37°C. After reaching confluence,
213 cells were plated in a 96-well plate (1.25 x 10⁵ cells/well, and enriched with acetylated LDL (50

214 $\mu\text{g/mL}$) and ^{14}C -free cholesterol ($0.3\mu\text{Ci} / \text{mL}$). After 48h, cells were washed with PBS
215 containing fatty acid-free albumin (FAFA) and equilibrated with DMEM containing FAFA for
216 24 hours. The cells were then washed twice and incubated with HDL ($50\mu\text{g ApoA-I/mL}$) for 8
217 hours. Media were collected and the radioactivity measured in a beta-scintillation counter. Cells
218 were rinsed twice with cold physiologic saline and the intracellular lipids extracted with hexane:
219 isopropanol (3:2, v/v). Solvent was evaporated and radioactivity measured. The percentage of
220 ^{14}C -CEC was calculated as (^{14}C -cholesterol in the medium/ ^{14}C -cholesterol in cells+medium)
221 $\times 100$.

222 **2.11. HDL-mediated platelet aggregation inhibition**

223 HDL ability to inhibit platelet aggregation was measured as described by Valiyaveetil
224 et al[22]. HDL (0.8mg protein/mL) was mildly oxidized by dialysis against PBS + $5\mu\text{M CuSO}_4$,
225 for 24h at 37°C . Citrated blood was drawn from a healthy donor and platelet-rich plasma (PRP)
226 obtained by centrifugation at 800rpm for 15 minutes. PRP was then incubated with native or
227 oxidized HDL (0.5 mg/mL) for 30 minutes at 37°C . Platelet aggregation was monitored using a
228 Lumi-Aggregometer type 500 VS (Chrono-log, Havertown, USA) for 6 minutes after the
229 addition of ADP ($5\mu\text{M}$). Results are expressed as percentage of the inhibition of platelet
230 aggregation induced by oxidized compared to native HDL.

231 **2.12. Statistical analysis**

232 The distribution of all variables was tested with Kolmogorov-Smirnov test. Jonckheere-
233 Terpstra trend in one-tail test was used to evaluate demographic, clinical variables and HDL
234 characterization among three groups clustered using BMI and expressed as median and
235 interquartile range. ANCOVA was used to perform comparisons among groups involving
236 enzymatic components of HDL adjusted for age, sex, and HOMA2 %S. Generalized linear
237 models with type III sums of squares were used to assess interactions of BMI within the
238 association between HDL functions and cIMT, the only outcome, adjusted for age, sex, HDL-C,
239 BMI, and HOMA2 %S. HDL functions and HDL-C were modeled with generalized linear
240 regression. The BMI effect on the cIMT among six HDL functions (HDL-C, HDL size,
241 antioxidant activity, CEC, HDL-mediated platelet inhibition, and anti-inflammatory activity)

242 was evaluated with the use of interaction tests. We used complete case analysis to handle
243 missing data. To construct the 3D surface plot 1, we included only HDL-C values between
244 40mg / dL and 100mg / dL; HDL size between 7.0 nm and 9.5 nm; CEC between 8% and 20%;
245 antioxidant activity between 0 and 100%. For the remainder of the regression analyzes, we used
246 the entire sample size of the sub-sample of 99 individuals. Two-sided $p \leq 0.05$ were considered to
247 indicate statistical significance. Analyses were performed using IBM SPSS[®] version 21.0
248 statistical software. Scatter plot was performed using GraphPad Prism version 7.0 for Mac,
249 GraphPad Software, La Jolla California USA, www.graphpad.com". Polinomial splines were
250 used to evaluate the relation between BMI or carotid IMT vs CEC or Antioxidant activity or a
251 compound variable, after transforming CEC and Antioxidant activity into positive z-scores. The
252 compound variable (Z-Efflux + Z-Antioxidant activity) was defined by the sum of z-scores for
253 CEC and antioxidant activity. In order to avoid overfitting, we excluded extreme values at x-
254 axis (<5th percentile and >95%percentile) and smoothing parameters for polinomial derivation
255 (degrees of freedom [df] and lambda) were defined after cross validation. Spline curves were
256 performed in R software, version 3.2.1 (R Foundation for Statistical Computing). We used
257 MATLAB[®] (version 4.10, The MathWorks, Inc, Apple Hill Drive Natick, MA) to fit a 3D
258 curve using second polynomial least square surface.

259

260 **3. Results**

261 ***3.1. Overall study participants characteristics***

262 The baseline characteristics of participants are shown in Table 1 stratified by BMI status
263 (n=899). The female gender prevailed among the participants and BMI values were associated
264 with waist circumference, increased cIMT and impaired metabolic parameters; *i.e.* lower HDL-
265 C, Apo-AI and HOMA2%S, as well as higher triglycerides, insulin and fasting glucose.
266 Similarly, a stepped increase in LDL-C and total cholesterol was also noted with increasing
267 BMI.

268 ***3.2. Association between BMI, HDL-C and cIMT***

269 In the whole studied sample (n=899), multivariable linear regression analyses adjusted for
270 BMI, age, gender, and plasma insulin or HOMA2-IR, confirmed the association between cIMT
271 and HDL-C ($\beta=-0.11$; 95%CI=-0.020;0.000; $p=0.03$) and identified the existence of a
272 significant interaction of BMI upon this association ($\beta=-1.80$; $p<0.0001$). To visualize the
273 pattern for such BMI interaction, 3D surface plots were applied based on second polynomial
274 least square regression (Figure 1). As shown in the Figure 1A, in subjects with increased BMI,
275 reduced HDL-C levels were associated with increased cIMT. In contrast, in those individuals
276 with reduced BMI, no clear association was found between HDL-C and cIMT. In order to
277 provide a deeper assessment of this interaction, a broad spectrum of HDL functions was
278 investigated in a subgroup of these individuals. As it would be expected, an inverse association
279 was found between BMI and HDL-C (Spearman's rho -0.028, $p < 0.0001$) and HDL size
280 (Spearman's rho -0.175, $p < 0.0001$).

281 *3.3. Association between BMI, HDL functions and cIMT in the subgroup analyses*

282 The subgroup characteristics are shown on Table 2. In the subgroup, we found a stepped
283 decrease of total HDL mass, HDL size, and HDL content in triglyceride, free cholesterol,
284 cholesteryl ester, and phospholipid across BMI categories (Table 3). PON activity adjusted for
285 the total number of HDL particles, *i.e.* PON/HDL-C ratio, increased in parallel with BMI
286 categories. There was no relation between BMI categories and activities of PLTP, LCAT, HL or
287 LPL (Table 3).

288 In line with previous studies, as shown in Figure 2A (linear beta -0.38, polynomial
289 $R^2=0.19$, $p=0.001$; Spearman's rho -0.32, $p<0.001$), we reported a progressive decline in CEC
290 as BMI increases. In contrast, we found a progressive increase in HDL antioxidant activity
291 which was proportional and reciprocal as compared with CEC (linear beta +1.38, polynomial
292 $R^2=0.12$, $p=0.04$) (Figure 2B). Both changes were mainly mediated by the HDL size which is
293 inversely related to weight gain. Based on this assumption, the compound variable of z-
294 transformed efflux plus antioxidant activity should remain approximately constant as HDL size
295 changes due to excess weight (p value 0.75) (Figure 2C). Increasing values of the compound

296 variable were associated lower carotid IMT (linear beta -0.10, polynomial R²=0.26, p<0.001)
297 (Figure 2D). Still, correlation analyses were made between BMI and HDL functions. An inverse
298 association was also found with HDL-mediated platelet inhibition (Spearman's rho -0.157, p <
299 0.03). No correlation was found between BMI and HDL anti-inflammatory activity (Spearman's
300 rho -0.009, p < 0.904) nor between each of the HDL functions.

301 Since both the abundance of substrate, *i.e.* triglyceride-rich lipoproteins, and the activities of
302 transport proteins are potentially involved in the effect of excess weight on HDL phenotype,
303 multivariate linear regression models were applied to estimate the influence of intravascular
304 HDL-remodeling proteins, *i.e.* CETP, LPL, HL, LCAT and PLTP on HDL size. CETP (β =-0.12;
305 95%CI=-0.30;-0.01; p=0.030), HL (β =-0.28; 95%CI=-0.35;-0.12; p<0.0001) and LCAT (β =-
306 0.36; 95%CI=-0.28;-0.13; p<0.0001) were drivers for HDL size. HDL size was also associated
307 with plasma triglycerides (β =-0.17; 95%CI=-0.06;-0.02; p<0.001), HOMA2-IR (β =0.21;
308 95%CI=0.01;0.42; p=0.001), PON activity/HDL-C (β =-0.33; 95%CI=-0.47;-0.13; p<0.0001)
309 and HDL-mediated antioxidant activity (β =-0.70; 95%CI=-0.81;-0.12; p=0.009). Association
310 was found between HOMA2-IR and HDL-mediated antioxidant activity (β =-2.1; 95%CI=-
311 3.66;-0.60; p=0.007).

312 In order to estimate the association between HDL functions and cIMT, we used multiple
313 linear regression with adjustments for the following confounders (BMI, age, sex, HDL-c and
314 insulin), which were selected based on univariate significance or clinical relevance (age, sex)
315 (Table 4). We observed a negative association between CEC and cIMT, which remained
316 significant after initial adjustment for the same confounders above, or even after adjustment for
317 HDL size (β =-0.18; 95%CI=-0.138; -0.011; p=0.02), antioxidant activity (β =-0.19; 95%CI=-
318 0.003;0.000; p=0.04) and PON activity/HDL-C (β =-0.16; 95%CI=-0.065;-0.002; p=0.02). The
319 antioxidant activity of HDL was also inversely related to cIMT. Anti-inflammatory activity,
320 PON activity/HDL-C and HDL-mediated platelet inhibition were not associated with cIMT in
321 an adjusted model.

322 Interactions of BMI were found within the linear associations between cIMT and CEC
323 (p=0.03), and cIMT and antioxidant activity (p=0.04). Although the 95% CI suggests a tendency

324 towards a moderating effect of the BMI on the association between HDL size and cIMT, this
325 interaction did not reach statistical significance ($p=0.13$) (Fig. 1B). As displayed in Fig 1C, the
326 inverse association between CEC and cIMT seems to increase in parallel with BMI values. In
327 contrast, as shown in Fig 1D, the inverse association between cIMT and antioxidant activity of
328 HDL increases with increasing BMI. In fact, the correlation between cIMT and antioxidant
329 activity is greater in individuals with BMI above the median (23.6 kg/m^2) ($r=-0.33$; $p=0.037$)
330 than in their counterparts ($r=-0.2$; $p=0.05$) while the correlation between CEC and cIMT is equal
331 in both subgroups (above, $r=-0.28$; $p=0.042$; below, $r=-0.28$; $p=0.016$).

332

333 **4. Discussion**

334

335 Recent data have shown that the predictive value of HDL-C for estimating the risk of
336 cardiovascular events declines after CVD manifestation[23]; a failure that has been attributed to
337 the increased generation of dysfunctional HDL in a setting of chronic or acute disease. As
338 pointed out in subjects with CVD, we hypothesized that excess weight may influence the
339 relationship between HDL-C and the risk of atherosclerotic disease. After confirming this
340 hypothesis, we moved forward investigating whether more subtle changes in the HDL system
341 could occur in overweight individuals and whether this could justify a change in the association
342 pattern between HDL-C and atherosclerotic disease. Taken together, our findings revealed the
343 following evidence: (i) the pattern of association between HDL-C and cIMT differs according to
344 the presence or absence of excess weight; (ii) increased BMI is associated with the simultaneous
345 change of multiple anti-atherosclerotic functions of HDL, including CEC and antioxidant
346 activity; (iii) the existing association between excess weight and carotid atherosclerotic burden
347 is in part attributable to HDL dysfunction; and (iv) HDL-mediated inhibition of platelet
348 aggregation declines with excess weight.

349 To the best of our knowledge, only few studies have previously assessed the impact of
350 body weight on HDL function in non-obese individuals and none used a simultaneous
351 assessment of multiple functions. In this clinical setting, CEC has been the main HDL function

352 assessed, which was investigated in interventional [3], case-control[24] and cross-sectional [5]
353 studies. In a large nested case-control study from the EPIC-Norfolk cohort, for example,
354 discrete changes in BMI in the overweight range was inversely correlated with CEC [24]. On
355 this specific aspect, our results are in line with previous studies.

356 Weight gain promotes a wide range of metabolic changes, among which insulin
357 resistance is the cornerstone for CVD risk. As a result of insulin resistance, for example, there is
358 an increase in the fatty acid efflux and in the activities of CETP and HL leading to a reduction
359 in HDL size, an increase in the ApoA-I catabolic rate and a reduction in CEC[5, 25, 26]. In
360 contrast with the evidence in obese subjects [27-29], our study did not identify changes in CETP
361 and HL activities across BMI categories although their activities were associated with HDL size
362 change. Thus, at this stage of excess weight, the biochemical and size changes in HDL particles
363 is more likely a consequence of increased substrate for HDL particle remodeling, *i.e.* increased
364 plasma concentration of triglyceride-rich lipoproteins.

365 These changes in the HDL system have traditionally been reported as a component
366 cause for the increased risk of CVD in obese individuals[30]. In those who are overweight but
367 below the obesity threshold, we revealed a similar scenario, *i.e.* insulin resistance inversely
368 relates with overweight, HDL size and CEC. It is interesting to note that these changes occurred
369 even before the threshold for overweight as defined by World Health Organization (WHO).
370 Thus, according to previous translational studies[31] or actuarial analyzes based on
371 observational cohorts[32], our data support the concept that the threshold for pathogenic body
372 mass is probably below the WHO definition.

373 Although it is clear that there is functional impairment, it is plausible that the change in
374 the HDL phenotype would have an adaptive biological purpose motivated by the chronic
375 increase of oxidative stress and by low-grade systemic inflammation. Similar reduction of HDL
376 size has been reported in individuals who exhibit acute phase response, such as in myocardial
377 infarction[33] and sepsis[34]. In these conditions, the reduction of HDL size is associated with a
378 greater capacity to mitigate the oxidative stress. In agreement with this and consistent with
379 previous studies, HDL size was inversely associated with increased antioxidant and PON

380 activities[35]. Interestingly, the predominance of small HDL (7.3-8.2 nm) in this cohort was
381 associated with an attenuated impact of BMI on cIMT. Hence, overweight-induced remodeling
382 in HDL simultaneously promoted the reduction of an anti-atherosclerotic mechanism, i.e. CEC,
383 and the increase of another, i.e. antioxidant activity, suggesting a biological response of the
384 HDL system to the predominant pro-atherosclerotic stimulus. Besides, the present study shows
385 that estimates of the magnitude of HDL participation in the CVD risk in excess weight are
386 naturally imprecise unless a broad range of anti-atherosclerotic functions is simultaneously
387 investigated.

388 Obesity is clearly shown to be a prothrombotic state resulting from a combination of
389 increased thrombin generation, platelet hyperactivity and decreased fibrinolysis[36]. Increased
390 platelet reactivity is the result of the interaction between multiple characteristics grouped into
391 obesity, including inflammation, oxidative stress, insulin resistance and adiposopathy with
392 change in adipokine secretion pattern. Our study added to this state of knowledge, a new
393 mechanism of imbalance in platelet activity; inhibition of HDL-mediated platelet aggregation
394 was inversely associated with BMI. This finding should be considered in the set of
395 prothrombotic changes of excess weight and as one of the mechanisms by which there is an
396 increase in the incidence of cardiovascular events in these individuals.

397 Among the main limitations in the present study lies the fact that it is based on a cross-
398 sectional design. In addition, due to the intensive laborious methodology involved in studying a
399 full breadth of HDL function and metabolic pathways, we may have not been able to maintain
400 the desired statistical power obtained as when the entire studied population was analyzed. In
401 spite of this, it does provide us a unique opportunity to evaluate the association between excess
402 weight and the HDL system early in the spectrum of metabolic derangement and atherogenesis.
403 In fact, this may especially be true given the low rates of insulin resistance and more favorable
404 lipid profile and systemic inflammatory activity of our study's participants.

405 In conclusion, our study indicates that higher BMI, even in non-obese, non-diabetic
406 individuals, is associated with decreased function of several protective activities of HDL. In
407 individuals with increased BMI, HDL dysfunction is directly associated with increased

408 atherosclerotic burden. Antioxidant activity is found to be an exception increasing with BMI
409 and it partially attenuated the atherosclerotic burden.

410 **Declaration of interest:** The authors declare no conflict of interest.

411 **Funding** The study was supported by São Paulo Research Foundation (FAPESP 2010/00201-8
412 and FAPESP 2006/60585-9 and CNPq (471380/2008-13). JCLJ was supported by a doctoral
413 grant from Coordination for the Improvement of Higher-Level Education Personnel (Capes
414 grant number PROEX0092045). NBP was supported by a doctoral grant (number 2012/01645-
415 2) from the Foundation for Research Support of the State of Sao Paulo (FAPESP). Prof Sposito
416 was supported by a fellowship grant of productivity in research from the National Council for
417 Scientific and Technological Development (CNPq) (grant number 301465/2017-7).

418 **Author contribution statement:** Jose Carlos de Lima-Junior drafted the manuscript and
419 participated on the analysis of the data, Vitor W.M. Virginio participated on the experiments,
420 Filipe A. Moura participated on the drafting of the manuscript and analysis of the data, Adriana
421 Bertolami participated on the experiments, Marcelo Bertolami participated critically reviewing
422 the manuscript, Wilson Nadruz participated critically reviewing the manuscript, Eliana Cota de
423 Faria participated on the experiments and analysis of the data, Ilaria Zanotti participated
424 critically reviewing the manuscript, Luiz Sergio F. de Carvalho participated on the analysis of
425 the data and critically reviewing the manuscript, Andrei C Sposito participated on the analysis
426 of the data and critically reviewing the manuscript

427 **Acknowledgements.** We thank Natalia B. Panzoldo from the University of Campinas for
428 technical assistance in HDL functions experiments.

429

430

431 **5. References**

- 432 [1] D.K. Tobias, A. Pan, C.L. Jackson, E.J. O'Reilly, E.L. Ding, W.C. Willett, J.E. Manson, F.B. Hu,
433 Body-mass index and mortality among adults with incident type 2 diabetes, *N Engl J Med*
434 370(3) (2014) 233-44.
- 435 [2] A. Afshin, M.H. Forouzanfar, M.B. Reitsma, P. Sur, K. Estep, A. Lee, L. Marczak, A.H.
436 Mokdad, M. Moradi-Lakeh, M. Naghavi, J.S. Salama, T. Vos, K.H. Abate, C. Abbafati, M.B.
437 Ahmed, Z. Al-Aly, A. Alkerwi, R. Al-Raddadi, A.T. Amare, A. Amberbir, A.K. Amegah, E. Amini,
438 S.M. Amrock, R.M. Anjana, J. Ärnlöv, H. Asayesh, A. Banerjee, A. Barac, E. Baye, D.A. Bennett,
439 A.S. Beyene, S. Biadgilign, S. Biryukov, E. Bjertness, D.J. Boneya, I. Campos-Nonato, J.J. Carrero,
440 P. Cecilio, K. Cercy, L.G. Ciobanu, L. Cornaby, S.A. Damtew, L. Dandona, R. Dandona, S.D.
441 Dharmaratne, B.B. Duncan, B. Eshrati, A. Esteghamati, V.L. Feigin, J.C. Fernandes, T. Fürst, T.T.
442 Gebrehiwot, A. Gold, P.N. Gona, A. Goto, T.D. Habtewold, K.T. Hadush, N. Hafezi-Nejad, S.I.
443 Hay, M. Horino, F. Islami, R. Kamal, A. Kasaeian, S.V. Katikireddi, A.P. Kengne, C.N.
444 Kesavachandran, Y.S. Khader, Y.H. Khang, J. Khubchandani, D. Kim, Y.J. Kim, Y. Kinfu, S. Kosen,
445 T. Ku, B.K. Defo, G.A. Kumar, H.J. Larson, M. Leinsalu, X. Liang, S.S. Lim, P. Liu, A.D. Lopez, R.
446 Lozano, A. Majeed, R. Malekzadeh, D.C. Malta, M. Mazidi, C. McAlinden, S.T. McGarvey, D.T.
447 Mengistu, G.A. Mensah, G.B.M. Mensink, H.B. Mezgebe, E.M. Mirrakhimov, U.O. Mueller, J.J.
448 Noubiap, C.M. Obermeyer, F.A. Ogbo, M.O. Owolabi, G.C. Patton, F. Pourmalek, M. Qorbani, A.
449 Rafay, R.K. Rai, C.L. Ranabhat, N. Reinig, S. Safiri, J.A. Salomon, J.R. Sanabria, I.S. Santos, B.
450 Sartorius, M. Sawhney, J. Schmidhuber, A.E. Schutte, M.I. Schmidt, S.G. Sepanlou, M.
451 Shamsizadeh, S. Sheikhbahaei, M.J. Shin, R. Shiri, I. Shiue, H.S. Roba, D.A.S. Silva, J.I. Silverberg,
452 J.A. Singh, S. Stranges, S. Swaminathan, R. Tabarés-Seisdedos, F. Tadese, B.A. Tedla, B.S.
453 Tegegne, A.S. Terkawi, J.S. Thakur, M. Tonelli, R. Topor-Madry, S. Tyrovolas, K.N. Ukwaja, O.A.
454 Uthman, M. Vaezghasemi, T. Vasankari, V.V. Vlassov, S.E. Vollset, E. Weiderpass, A.
455 Werdecker, J. Wesana, R. Westerman, Y. Yano, N. Yonemoto, G. Yonga, Z. Zaidi, Z.M. Zenebe,
456 B. Zipkin, C.J.L. Murray, G.O. Collaborators, Health Effects of Overweight and Obesity in 195
457 Countries over 25 Years, *N Engl J Med* 377(1) (2017) 13-27.
- 458 [3] A.A. Khan, P.A. Mundra, N.E. Straznicki, P.J. Nestel, G. Wong, R. Tan, K. Huynh, T.W. Ng,
459 N.A. Mellett, J.M. Weir, C.K. Barlow, Z.H. Alshehry, G.W. Lambert, B.A. Kingwell, P.J. Meikle,
460 Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-
461 Density Lipoprotein Functionality in Metabolic Syndrome, *Arterioscler Thromb Vasc Biol* 38(2)
462 (2018) 438-447.
- 463 [4] F.M. Sacks, M.K. Jensen, From High-Density Lipoprotein Cholesterol to Measurements of
464 Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in
465 Cardiovascular Disease, *Arterioscler Thromb Vasc Biol* 38(3) (2018) 487-499.
- 466 [5] T. Sasahara, P. Nestel, N. Fidge, D. Sviridov, Cholesterol transport between cells and high
467 density lipoprotein subfractions from obese and lean subjects, *J Lipid Res* 39(3) (1998) 544-54.
- 468 [6] N. Attia, N. Fournier, B. Védie, M. Cambillau, P. Beaune, O. Ziegler, A. Grynberg, J.L. Paul, B.
469 Guerci, Impact of android overweight or obesity and insulin resistance on basal and
470 postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities, *Atherosclerosis*
471 209(2) (2010) 422-9.
- 472 [7] A.C. Sposito, HDL metrics, let's call the number thing off?, *Atherosclerosis* 251 (2016) 525-
473 527.
- 474 [8] J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA)
475 evaluation uses the computer program, *Diabetes Care* 21(12) (1998) 2191-2.
- 476 [9] A. Bertolami, J.C. de Lima-Júnior, R.M. Cintra, L.S. Carvalho, C.C. Gonzaga, M.L. Sulzbach,
477 A.C.G.P. Petisco, J.E.M. Barbosa, A.A. Faludi, J. Plutzky, M.C. Bertolami, A.C. Sposito,
478 Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in
479 overweight subjects, *Clin Endocrinol (Oxf)* (2017).

- 480 [10] J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, S.S. Najjar, C.M.
481 Rembold, W.S. Post, F. American Society of Echocardiography Carotid Intima-Media Thickness
482 Task, Use of carotid ultrasound to identify subclinical vascular disease and evaluate
483 cardiovascular disease risk: a consensus statement from the American Society of
484 Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for
485 Vascular Medicine, *Journal of the American Society of Echocardiography* : official publication
486 of the American Society of Echocardiography 21(2) (2008) 93-111; quiz 189-90.
- 487 [11] M.W. Lorenz, S. von Kegler, H. Steinmetz, H.S. Markus, M. Sitzer, Carotid intima-media
488 thickening indicates a higher vascular risk across a wide age range: prospective data from the
489 Carotid Atherosclerosis Progression Study (CAPS), *Stroke* 37(1) (2006) 87-92.
- 490 [12] M.J. Chapman, S. Goldstein, D. Lagrange, P.M. Laplaud, A density gradient ultracentrifugal
491 procedure for the isolation of the major lipoprotein classes from human serum, *J Lipid Res*
492 22(2) (1981) 339-58.
- 493 [13] E.S. Lima, R.C. Maranhao, Rapid, simple laser-light-scattering method for HDL particle
494 sizing in whole plasma, *Clin Chem* 50(6) (2004) 1086-8.
- 495 [14] L. Lagrost, Determination of the mass concentration and the activity of the plasma
496 cholesteryl ester transfer protein (CETP), *Methods Mol Biol* 110 (1998) 231-41.
- 497 [15] M. Jauhainen, C. Ehnholm, Determination of human plasma phospholipid transfer protein
498 mass and activity, *Methods* 36(2) (2005) 97-101.
- 499 [16] C. Ehnholm, T. Kuusi, Preparation, characterization, and measurement of hepatic lipase,
500 *Methods Enzymol* 129 (1986) 716-38.
- 501 [17] J.W. Chisholm, A.K. Gebre, J.S. Parks, Characterization of C-terminal histidine-tagged
502 human recombinant lecithin:cholesterol acyltransferase, *J Lipid Res* 40(8) (1999) 1512-9.
- 503 [18] D.Z. Scherrer, V.H. Zago, I.C. Vieira, E.S. Parra, N.B. Panzoldo, F. Alexandre, R. Secolin, J.
504 Baracat, E.C. Quintão, E.C. Faria, p.Q192R SNP of PON1 seems not to be Associated with
505 Carotid Atherosclerosis Risk Factors in an Asymptomatic and Normolipidemic Brazilian
506 Population Sample, *Arq Bras Cardiol* 105(1) (2015) 45-52.
- 507 [19] M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy, A.M. Fogelman, A cell-
508 free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating
509 oxidized phospholipids, *J Lipid Res* 42(8) (2001) 1308-17.
- 510 [20] C. Besler, K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D.M. Shih, A. Chroni, K.
511 Yonekawa, S. Stein, N. Schaefer, M. Mueller, A. Akhmedov, G. Daniil, C. Manes, C. Templin, C.
512 Wyss, W. Maier, F.C. Tanner, C.M. Matter, R. Corti, C. Furlong, A.J. Lusis, A. von Eckardstein,
513 A.M. Fogelman, T.F. Luscher, U. Landmesser, Mechanisms underlying adverse effects of HDL
514 on eNOS-activating pathways in patients with coronary artery disease, *J Clin Invest* 121(7)
515 (2011) 2693-708.
- 516 [21] A. Machado-Lima, R.T. Iborra, R.S. Pinto, C.H. Sartori, E.R. Oliveira, E.R. Nakandakare, J.T.
517 Stefano, D. Giannella-Neto, M.L. Correa-Giannella, M. Passarelli, Advanced glycated albumin
518 isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene
519 expression impairing ABCA-1-mediated reverse cholesterol transport, *Diabetes Metab Res Rev*
520 29(1) (2013) 66-76.
- 521 [22] M. Valiyaveetil, N. Kar, M.Z. Ashraf, T.V. Byzova, M. Febbraio, E.A. Podrez, Oxidized high-
522 density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI, *Blood*
523 111(4) (2008) 1962-71.
- 524 [23] G. Silbernagel, B. Schottker, S. Appelbaum, H. Scharnagl, M.E. Kleber, T.B. Grammer, A.
525 Ritsch, U. Mons, B. Holleczeck, G. Goliash, A. Niessner, B.O. Boehm, R.B. Schnabel, H. Brenner,
526 S. Blankenberg, U. Landmesser, W. Marz, High-density lipoprotein cholesterol, coronary artery
527 disease, and cardiovascular mortality, *Eur Heart J* 34(46) (2013) 3563-71.
- 528 [24] D. Saleheen, R. Scott, S. Javad, W. Zhao, A. Rodrigues, A. Picataggi, D. Lukmanova, M.L.
529 Mucksavage, R. Luben, J. Billheimer, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, N. Wareham,
530 D.J. Rader, Association of HDL cholesterol efflux capacity with incident coronary heart disease
531 events: a prospective case-control study, *Lancet Diabetes Endocrinol* 3(7) (2015) 507-13.

- 532 [25] E.S. Parra, N.B. Panzoldo, V.H. Zago, D.Z. Scherrer, F. Alexandre, J. Bakkarat, V.S. Nunes,
533 E.R. Nakandakare, E.C. Quintao, W. Nadruz, Jr., E.C. de Faria, A.C. Sposito, HDL size is more
534 accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals
535 classified as low cardiovascular risk, *PLoS One* 9(12) (2014) e114212.
- 536 [26] M. de la Llera Moya, F.C. McGillicuddy, C.C. Hinkle, M. Byrne, M.R. Joshi, V. Nguyen, J.
537 Tabita-Martinez, M.L. Wolfe, K. Badellino, L. Pruscino, N.N. Mehta, B.F. Asztalos, M.P. Reilly,
538 Inflammation modulates human HDL composition and function in vivo, *Atherosclerosis* 222(2)
539 (2012) 390-4.
- 540 [27] T. Arai, S. Yamashita, K. Hirano, N. Sakai, K. Kotani, S. Fujioka, S. Nozaki, Y. Keno, M.
541 Yamane, E. Shinohara, Increased plasma cholesteryl ester transfer protein in obese subjects. A
542 possible mechanism for the reduction of serum HDL cholesterol levels in obesity, *Arterioscler*
543 *Thromb* 14(7) (1994) 1129-36.
- 544 [28] C.F. Ebenbichler, M. Laimer, S. Kaser, A. Ritsch, A. Sandhofer, H. Weiss, F. Aigner, J.R.
545 Patsch, Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein
546 profile in morbidly obese women, *Arterioscler Thromb Vasc Biol* 22(9) (2002) 1465-9.
- 547 [29] C.P.J. Talbot, J. Plat, P.J. Joris, M. Konings, Y.H.A.M. Kusters, C.G. Schalkwijk, A. Ritsch, R.P.
548 Mensink, HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with
549 body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally
550 obese men, *Atherosclerosis* 274 (2018) 23-28.
- 551 [30] B. Shao, C. Tang, A. Sinha, P.S. Mayer, G.D. Davenport, N. Brot, M.N. Oda, X.Q. Zhao, J.W.
552 Heinecke, Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced
553 high-density lipoprotein oxidation by myeloperoxidase, *Circ Res* 114(11) (2014) 1733-42.
- 554 [31] L.H. Bogl, S.M. Kaye, J.T. Ramo, A.J. Kangas, P. Soininen, A. Hakkarainen, J. Lundbom, N.
555 Lundbom, A. Ortega-Alonso, A. Rissanen, M. Ala-Korpela, J. Kaprio, K.H. Pietilainen, Abdominal
556 obesity and circulating metabolites: A twin study approach, *Metabolism* 65(3) (2016) 111-21.
- 557 [32] K. Bhaskaran, I. Dos-Santos-Silva, D.A. Leon, I.J. Douglas, L. Smeeth, Association of BMI
558 with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults
559 in the UK, *Lancet Diabetes Endocrinol* (2018).
- 560 [33] L.S. Carvalho, V.W. Virginio, N.B. Panzoldo, V.N. Figueiredo, S.N. Santos, R.G. Modolo, J.M.
561 Andrade, E.S.J.C. Quinaglia, W. Nadruz-Junior, E.C. de Faria, A.C. Sposito, G. Brasilia Heart
562 Study, Elevated CETP activity during acute phase of myocardial infarction is independently
563 associated with endothelial dysfunction and adverse clinical outcome, *Atherosclerosis* 237(2)
564 (2014) 777-83.
- 565 [34] A. Pirillo, A.L. Catapano, G.D. Norata, HDL in infectious diseases and sepsis, *Handb Exp*
566 *Pharmacol* 224 (2015) 483-508.
- 567 [35] A. Kontush, S. Chantepie, M.J. Chapman, Small, dense HDL particles exert potent
568 protection of atherogenic LDL against oxidative stress, *Arterioscler Thromb Vasc Biol* 23(10)
569 (2003) 1881-8.
- 570 [36] F. Santilli, N. Vazzana, R. Liani, M.T. Guagnano, G. Davi, Platelet activation in obesity and
571 metabolic syndrome, *Obes Rev* 13(1) (2012) 27-42.

572

573

574 **Figure 1. 3D surface plot showing the association between BMI, cIMT, and HDL**
575 **variables.** This surface plot displays an image based on the relationship between the BMI and
576 HDL variables as predictors on the x- and y-axes and a continuous surface that represents the
577 cIMT values on the z-axis. The peak on the plot corresponds with the yellow color and the
578 highest value obtained to cIMT using the combination of X and Y that produce the maxima
579 cIMT, which occurs at approximately 0.8mm. The valley corresponds with blue color and the
580 combination of X and Y that produce the minima cIMT. Figure 1A, HDL-C values. Figure 1B,
581 HDL size. Figure 1C, CEC values. Figure 1D, antioxidant activity of HDL. HDL-C, high-
582 density lipoprotein cholesterol in mg/dL. BMI, body mass index in kg/m^2 . CEC is expressed as
583 a percentage of efflux in the sample, normalized to a reference sample. Antioxidant activity is
584 expressed in % as inhibition of LDL oxidation in the presence of each subject's HDL oxidation.
585 **Figure 2. Polynomial splines showing the associations between BMI, cIMT and HDL**
586 **variables.** 2A, CEC according to BMI values. 2B, Antioxidant activity according to BMI
587 values. 2C, compound variable (Z-Efflux + Z-Antioxidant activity) according to BMI values.
588 2D, cIMT values according to compound variable (Z-Efflux + Z-Antioxidant activity). Gray
589 shading indicates 95% confidence intervals.

590

591

592

593

594

595

596

597

598

599

600

601

602 **Table 1.** Clinical characteristics according to BMI groups

	BMI categories (kg/m²)			<i>p-value</i>
	<22	22-24.99	25-30	
Sample size	186	264	449	
BMI, kg/m²	20.6 (1.8)	23.6 (1.6) ^a	28 (4.6) ^{b,c}	<0.0001
Waist circumference, cm	68 (9)	75 (11) ^a	94 (19) ^{b,c}	<0.0001
Age, yr	38 (24)	45.5 (26) ^a	54 (16) ^b	0.003
Male sex, %	43.5	44.7	39.6	0.369
Hypertension, %	28.6	31.3	28.3	0.915
Glucose, mg/dL	81 (12.0)	86 (14.0) ^a	105 (62.0) ^{b,c}	<0.0001
Insulin, μU/mL	3.0 (2.5)	4.7 (4.9) ^a	10.2 (8.2) ^{b,c}	<0.0001
HOMA2 % β	61.9 (38.2)	61.3 (49.4)	64.9 (51.3) ^{b,c}	0.008
HOMA2 %S	241.7 (210.3)	161.2 (183.5)	68.8 (62.5) ^{b,c}	<0.0001
HOMA2-IR	0.46 (0.4)	0.51 (0.5)	0.66 (0.5) ^{b,c}	<0.0001
CRP, mg/dL	0.42 (0.9)	0.70 (1.1)	0.51 (1.0)	0.453
Triglycerides, mg/dL	66 (34)	81 (46) ^a	118 (87) ^{b,c}	<0.0001
LDL-C, mg/dL	95 (40)	104 (34) ^a	107 (42) ^b	<0.0001
Total cholesterol, mg/dL	175 (53)	181 (50)	187 (55) ^{b,c}	< 0.0001
ApoA-I, mg/dL	148 (53)	142 (46)	137 (38) ^{b,c}	<0.0001
ApoB, mg/dL	72 (23)	81 (27) ^a	90 (31) ^b	<0.0001
HDL-C, mg/dL	63 (29)	52 (30) ^a	45 (19) ^{b,c}	<0.0001

cIMT, mm	0.55 (0.20)	0.60 (0.20) ^a	0.70 (0.24) ^{b,c}	< 0.0001
-----------------	-------------	--------------------------	----------------------------	----------

603

604 All continuous variables are expressed as medians and interquartile ranges, and categorical
605 variables as percentages. Comparisons between groups were analyzed with Jonckheere–
606 Terpstra’s for ordered alternatives with pairwise comparisons, or Chi-Square test for the
607 categorical variables. To convert the values for glucose to millimoles per liter, divide by 18.
608 To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the
609 values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for
610 triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI
611 >25 vs 22 – 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629 **Table 2.** Subgroup clinical characteristics according to BMI groups

BMI categories (kg/m²)					
	<22	22-24.99	25-30	<i>p-value</i>	
Sample size	34	47	20		
BMI, kg/m²		20.0 (2.5)	23.5 (1.6)^a	26.7 (2.55)^{b,c}	<0.0001
Waist circumference, cm		65.0 (7.0)	75.5 (13.2) ^a	84.0 (10.5) ^{b,c}	<0.0001
Age, yr		42 (21)	39 (20.7)	47 (9.5)	0.24
Male sex, %		33.7	46.5	19.8	0.47
Glucose, mg/dL		80.0 (8.0)	83.0 (9.2)	86.0 (11.5) ^b	0.012
Insulin, μU/mL		2.5 (2.0)	4.3 (4.0) ^a	5.8 (6.0) ^{b,c}	<0.0001
HOMA2 % β		58.4 (37.8)	69.0 (45.9)	84.9 (38.7) ^b	<0.0001
HOMA2 %S		303.2 (261.6)	228.2 (221.9) ^a	148.2 (75.1) ^{b,c}	<0.0001
HOMA2-IR		0.3 (0.3)	0.4 (0.5) ^a	0.7 (0.5) ^{b,c}	<0.0001
CRP, mg/dL		0.9 (1.5)	0.71 (1.2)	0.6 (1.2)	0.51
Triglycerides, mg/dL		57.0 (27.2)	70.0 (29.0)	123.5 (72.7) ^{b,c}	<0.0001
LDL-C, mg/dL		98.0 (30.5)	100.0 (34.0)	101.0 (28.5)	0.57
Total cholesterol, mg/dL		181.0 (48.7)	169.0 (42.0)	173.0 (34.5)	0.13
ApoA-I, mg/dL		176.0 (61.2)	147.0 (53.0)	111.0 (57.2) ^{b,c}	<0.0001
ApoB, mg/dL		73.7 (24.3)	81.3 (26.1)	81.7 (22.3) ^b	0.04
HDL-C, mg/dL		72.5 (39.0)	49.0 (52.0) ^a	32.5 (15.0) ^{b,c}	<0.0001
cIMT, mm		0.55 (0.2)	0.58 (0.2)	0.67 (0.5)	0.05

630

631 All continuous variables are expressed as medians and interquartile ranges, and categorical
632 variables as percentages. Comparisons between groups were analyzed with Jonckheere–
633 Terpstra’s for ordered alternatives with pairwise comparisons, or Chi-Square test for the
634 categorical variables. To convert the values for glucose to millimoles per liter, divide by 18.
635 To convert the values for insulin to picomoles per liter, multiply by 6.945. To convert the
636 values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for
637 triglycerides to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI
638 >25 vs 22 – 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656 **Table 3.** HDL characterization

	BMI categories (kg/m²)			<i>p-value</i>
	<22	22-24.99	25-30	
Sample size	34	47	20	
Total mass, mg/dL	198.8 (91)	182.3 (98)	155 (99) ^c	0.024
Triglycerides, mg/dL	9.8 (6.0)	7.8 (4.0)	8.3 (6)	0.047
Free cholesterol, mg/dL	8.0 (6.0)	6.3 (4.0) ^a	5.3 (3.0) ^c	0.001
Cholesteryl ester, mg/dL	60.1 (35)	52.9 (46)	39.7 (26) ^c	0.004
Phospholipids, mg/dL	35.1 (19)	29.2 (14) ^a	24.7 (13) ^c	<0.0001
ApoA-I, mg/dL	86.1 (40)	86.1 (48)	76.9 (39)	0.578
Total proteins, mg/dL	135.5 (71.5)	143.6 (74)	147.0 (54.0)	0.777
HDL size, nm	7.9 (0.9)	7.8 (0.9)	7.6 (0.8) ^{b,c}	<0.0001
Zeta potential, mV	-7.7 (5)	-6.4 (4)	-7.8 (9)	0.297
CETP, %	10.1 (6.4)	10.6 (7.3)	10.7 (6.3)	0.612
PLTP, μmol PC/mL/h	5.7 (2.9)	6.0 (3.2)	5.4 (3.5)	0.338
LCAT, nmol CE/mL/h	17.4 (15)	16.6 (12)	16.9 (19)	0.454
LPL, μmol FFA/mL/h	4.0 (3.4)	3.7 (3.7)	3.2 (2.9)	0.157
HL, μmol FFA/mL/h	4.9 (4.0)	5.8 (4.4)	5.8 (4.5)	0.440
PON/HDL-C, (mmol/min)/(mg/dL)	0.40 (0.5)	0.50 (0.7) ^a	0.54 (0.7) ^c	<0.001

657

658 All continuous variables are expressed as medians and interquartile ranges. To convert values
659 for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides
660 to millimoles per liter, multiply by 0.01129. ^aBMI 22 – 24.9 vs BMI <22; ^bBMI >25 vs 22 –
661 24.9; ^cBMI > 25 vs BMI < 22. Significant p-value < 0.05.

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686 Table 4. Linear regression analyses between HDL functions and cIMT

Independent variable	Unstandardized β	Standardized β	Lower CI 95%	Upper CI 95%	<i>p</i> -value
Antioxidant activity					
Unadjusted					
Adjusted ^a	-0.001	-0.153	-0.003	0.000	0.128
	-0.002	-0.196	-0.003	0.000	0.038
CEC					
Unadjusted	-0.016	-0.260	-0.028	-0.004	0.009
Adjusted ^a	-0.012	-0.188	-0.023	0.000	0.047
PON/HDL-C					
Unadjusted	-0.010	-0.063	-0.079	0.024	0.301
Adjusted ^a	-0.045	-0.061	-0.071	0.019	0.254
Anti-inflammatory activity					
Unadjusted	0.000	-0.043	-0.003	0.002	0.676
Adjusted ^a	0.000	-0.004	-0.002	0.002	0.963
HDL-mediated platelet inhibition					
Unadjusted	0.002	0.164	0.000	0.004	0.120
Adjusted ^a	0.002	0.177	0.000	0.004	0.068

^b Adjusted for age, sex, BMI, HDL-C and insulin. In order to compare effects across different HDL functions we provided the standardized coefficients.


687

688


689

690


A.




B.




C.




D.




A Smoothing spline with 3 df selected by cross validation; $R^2 = 0.19$



B Smoothing spline with 3 df selected by cross validation; $R^2 = 0.12$



C Smoothing spline with 2 df selected by cross validation; $R^2 = 0.05$



D Smoothing spline with 4 df selected by cross validation; $R^2 = 0.25$

